Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$109.65 +1.3%	$102.59	$76.53 ▼ $131.49	$26.02B	1.29	942,387 shs	613,718 shs
NVAX Novavax	$6.80 +0.5%	$6.76	$5.01 ▼ $17.81	$1.09B	2.69	6.30 million shs	2.29 million shs
PFE Pfizer	$25.45 +0.5%	$23.67	$20.92 ▼ $31.54	$143.95B	0.58	41.63 million shs	27.10 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+0.70%	+3.30%	-4.28%	+17.66%	+37.46%
NVAX Novavax	+2.27%	+4.32%	-4.38%	+20.71%	-47.88%
PFE Pfizer	+1.16%	+4.24%	+8.00%	+4.22%	-9.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	2.5573 of 5 stars	4.4	2.0	0.0	0.0	1.8	0.8	0.0
NVAX Novavax	4.5088 of 5 stars	3.1	2.0	0.0	4.7	1.3	0.8	3.1
PFE Pfizer	4.9745 of 5 stars	3.2	3.0	4.2	4.3	2.8	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.83	Moderate Buy	$137.86	25.73% Upside
NVAX Novavax	2.29	Hold	$17.00	150.18% Upside
PFE Pfizer	2.45	Hold	$28.55	12.20% Upside

Current Analyst Ratings Breakdown

Latest BNTX, NVAX, and PFE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$138.00
6/17/2025	NVAX Novavax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00
6/16/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$145.00 ➝ $138.00
6/5/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$134.00 ➝ $145.00
6/3/2025	BNTX BioNTech	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$151.00 ➝ $155.00
6/2/2025	BNTX BioNTech	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$112.00
5/29/2025	BNTX BioNTech	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Neutral	$110.00
5/29/2025	PFE Pfizer	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold	$28.00 ➝ $25.00
5/22/2025	BNTX BioNTech	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$120.00 ➝ $116.00
5/22/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$134.00 ➝ $134.00
5/21/2025	PFE Pfizer	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $33.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.98B	8.85	N/A	N/A	$87.61 per share	1.25
NVAX Novavax	$682.16M	1.61	N/A	N/A	($3.89) per share	-1.75
PFE Pfizer	$63.63B	2.27	$4.39 per share	5.80	$15.62 per share	1.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$719.92M	-$3.40	N/A	N/A	N/A	-27.37%	-3.94%	-3.41%	8/4/2025 (Estimated)
NVAX Novavax	-$187.50M	$2.65	2.56	84.94	0.06	38.14%	-115.51%	29.99%	8/14/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	18.44	8.40	0.92	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest BNTX, NVAX, and PFE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	NVAX Novavax	$0.71	$2.93	+$2.22	$2.93	$204.08 million	$666.66 million
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.76%	N/A	124.64%	16 Years

Latest BNTX, NVAX, and PFE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	10.18	10.02
NVAX Novavax	N/A	2.06	2.03
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
NVAX Novavax	53.04%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
NVAX Novavax	1.00%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	6,772	240.39 million	194.24 million	Optionable
NVAX Novavax	1,990	161.97 million	160.35 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

BNTX, NVAX, and PFE Headlines

Recent News About These Companies

Stocks At All-Time Highs – Grab Your Gains and Buy These 7% Dividend Gems

July 3 at 4:33 PM | 247wallst.com

Pfizer’s New Pneumococcal Vaccine Study: A Potential Game Changer for Children’s Health

July 3 at 12:20 PM | tipranks.com

Pfizer’s ARV-471: A Promising New Hope for Advanced Breast Cancer

July 3 at 12:20 PM | tipranks.com

Pfizer: Options Activity Speaks Bullish

July 3 at 10:36 AM | seekingalpha.com

Pfizer: Options Activity Speaks Bullish

July 3 at 10:02 AM | seekingalpha.com

Pfizer Trades Above 50-Day Average for a Month: Time to Buy?

July 3 at 9:51 AM | zacks.com

D.A. Davidson & CO. Has $49.12 Million Stock Position in Pfizer Inc. (NYSE:PFE)

July 3 at 8:46 AM | marketbeat.com

Mutual Advisors LLC Buys 20,583 Shares of Pfizer Inc. (NYSE:PFE)

July 3 at 8:25 AM | marketbeat.com

Teacher Retirement System of Texas Buys 361,603 Shares of Pfizer Inc. (NYSE:PFE)

July 3 at 7:29 AM | marketbeat.com

First Horizon Advisors Inc. Has $20.91 Million Stock Position in Pfizer Inc. (NYSE:PFE)

July 3 at 7:08 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Purchased by WCM Investment Management LLC

July 3 at 5:38 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Bought by DAVENPORT & Co LLC

July 3 at 5:18 AM | marketbeat.com

Is Pfizer Stock a Yield Trap?

July 3 at 4:28 AM | fool.com

Pfizer (PFE) Outperforms Broader Market: What You Need to Know

July 2 at 6:46 PM | zacks.com

Huge Unusual Volume In Pfizer Put Options Signals Investors Bullish Outlook

July 2 at 3:48 PM | talkmarkets.com

Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons

July 2 at 2:06 PM | benzinga.com

Republicans subpoena former Pfizer exec over timing of COVID vaccine clinical tests

July 2 at 1:25 PM | msn.com

Pfizer’s New Study on Mevrometostat and Enzalutamide: Potential Game-Changer in Prostate Cancer Treatment?

July 2 at 12:41 PM | tipranks.com

Pfizer’s Phase 3 RSV Vaccine Study: A Potential Game-Changer for Maternal and Infant Health

July 2 at 12:41 PM | tipranks.com

Kanawha Capital Management LLC Purchases 24,026 Shares of Pfizer Inc. (NYSE:PFE)

July 2 at 9:08 AM | marketbeat.com

House Subpoenas Ex-Pfizer Scientist in Election Meddling Probe

July 2 at 8:25 AM | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX, NVAX, and PFE Company Descriptions

BioNTech NASDAQ:BNTX

$109.64 +1.39 (+1.28%)

Closing price 03:53 PM Eastern

Extended Trading

$109.64 0.00 (0.00%)

As of 04:53 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Novavax NASDAQ:NVAX

$6.80 +0.04 (+0.52%)

Closing price 03:58 PM Eastern

Extended Trading

$6.82 +0.03 (+0.44%)

As of 04:59 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Pfizer NYSE:PFE

$25.44 +0.13 (+0.49%)

Closing price 03:59 PM Eastern

Extended Trading

$25.42 -0.03 (-0.11%)

As of 05:00 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time